Key statistics
On Monday, Acumen Pharmaceuticals Inc (ABOS:NSQ) closed at 2.37, 30.93% above the 52 week low of 1.81 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.51 |
---|---|
High | 2.51 |
Low | 2.36 |
Bid | 2.20 |
Offer | 2.58 |
Previous close | 2.50 |
Average volume | 154.63k |
---|---|
Shares outstanding | 60.08m |
Free float | 53.33m |
P/E (TTM) | -- |
Market cap | 150.20m USD |
EPS (TTM) | -1.11 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
- Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
- Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
- Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
- Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
- Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
- Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
More ▼